Society of Diabetic Nephropathy Prevention Journal of Nephropharmacology 2345-4202 14 1 2025 01 01 Renoprotective efficacy of montelukast; an overview on recent advancements e12759 e12759 10.34172/npj.2025.12759 EN Sayed Yousef Mojtahedi https://orcid.org/0000-0002-6231-2662 Maryam Ghodsi Paniz Pourpashang https://orcid.org/0000-0003-4469-086X Journal Article 10.34172/npj.2025.12759 2024 09 17 2024 11 30 Montelukast holds significant promise as a renoprotective agent, especially in early-stage kidney injuries. Its multifaceted mechanisms—ranging from anti-inflammatory and antioxidant actions to neutrophil inhibition—underscore its potential utility in clinical settings. Montelukast should not be used in patients with a known hypersensitivity to the drug or its components. Caution is advised for individuals with a history of psychiatric disorders or those who have phenylketonuria (PKU), as some formulations contain phenylalanine.